SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Who May Qualify: - Diagnosis of T2D; - Aged ≥18 years; - Body mass index \> 18.5 kg/m2; - Drug naïve, or managed with metformin monotherapy and willing to be randomised to either dapagliflozin or metformin; - eGFR ≥45 ml/min/1,73m2; and - Signed willing to sign a consent form. Who Should NOT Join This Trial: - Have an immediate need for rapid intensification of glucose lowering therapy due to marked hyperglycaemia; or - There is a definite indication for, or contraindication to, either metformin or SGLT2 inhibitor; or - They have clearly documented coronary artery disease (defined as a previous acute coronary syndrome, coronary stent or bypass surgery) or clearly documented heart failure (defined on the basis of a hospital admission, specialist diagnosis or an echocardiogram or other imaging modality); or - Pregnant or breast-feeding. Always talk to your doctor about whether this trial is right for you.